Another bend in the road for Prosensa suggests new path for drisapersen
In a move that could potentially signal greater flexibility by regulators in reviewing groundbreaking drugs with new mechanisms of action in rare diseases with clear unmet medical need, the FDA provided guidance for a potential regulatory path, under accelerated approval, for drisapersen.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST